Lineage Cell Therapeutics, Inc. (LCTX) Presents at H.C. Wainwright 27th

Sara Nik
Analysis Analyst

And welcome to our subsequent session. I am the moderator, Sara Nik, an Fairness Analysis VP at H.C. Wainwright. And it is my pleasure to introduce our subsequent presenter, Brian Culley, CEO of Lineage Cell Therapeutics, a medical stage biotechnology firm creating novel cell therapies for neurological and ophthalmic circumstances. Brian, the ground is yours.

Brian Culley
CEO, President & Director

Thanks a lot, and good morning, everyone. It is a pleasure to be right here. All proper. Subsequent slide. In order we’re a publicly traded firm and I’ll make some forward-looking statements, please consult with our protected harbor data filed at medical trials — excuse me, that was ironic — sec.gov. You may also go to clinicaltrials.gov.

All proper. So Lineage Cell Therapeutics. I’ll go in a short time immediately as a result of I need to squeeze in a few new issues that you have not heard introduced from the corporate earlier than. We had some bulletins. However as a normal matter, Lineage Cell Therapeutics is devoted to the manufacture and supply of particular cell varieties. And we’re doing this with the intention to handle circumstances and indications the place the lack of a sure cell sort provides rise to the illness. The best and greatest use case for this to this point for us has been within the setting of dry age-related macular degeneration. This illness, the hallmark is the lack of RPE cells. We manufacture RPE cells within the laboratory and ship them to sufferers with the intention to restore the perform that is misplaced in that situation.

The pipeline, that is